Zucara Therapeutics is developing a once-daily therapeutic aimed at preventing hypoglycemia in people with diabetes. The self-described goal is to improve patient health and quality of life.

Zucara Therapeutics

Viewport Meta

IPhone / Mobile Compatible

SSL by Default

Google Tag Manager

Google Font API

Google Analytics

WordPress

LetsEncrypt

DoubleClick.Net

Business Management

Michael Midmer

Richard Liggins

Healthcare

Susan Peers

Manager, Scientific Programs

Eric Simonson

Michael Martin

Michael Riddell

Co Founder and Chief Scientific Officer

Companies With Fewer Than 100 Employees (Top 10K)

Vancouver Companies With Fewer Than 100 Employees

University of British Columbia Alumni Founded Companies

Canada Early Stage Companies With More Than $1M in Revenue

Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type 1 diabetes is not properly controlled. It has demonstrated potential to specifically block somatostatin type 2 receptors in the pancreas thereby preventing hypoglycemia and restoring natural glucose levels in the blood. Zucara’s method offers a clear advantage to patients as a preventative measure whereas current drug therapies can only rescue a patient already experiencing potentially dangerous low blood sugar.

Sanofi

Series B - Zucara Therapeutics

JDRF (The Juvenile Diabetes Research Foundation)

Grant - Zucara Therapeutics

Canadian Glycomics Network

Mitacs

Perceptive Advisors

Series A - Zucara Therapeutics

The Leona M. and Harry B. Helmsley Charitable Trust

National Research Council of Canada Industrial Research Assistance Program

Venture Round - Zucara Therapeutics

Pre Seed Round - Zucara Therapeutics

Vancouver

British Columbia

Canada

North America

Zucara Therapeutics Announces Strategic Investment from Sanofi as Part of US$20 Million Series B Financing

Sanofi and Perceptive Advisors Back Zucara Therapeutics Inc. with $20 Million Investment

Severe Hypoglycemia Pipeline Assessment | In-depth Insights Into the Clinical Trials, Emerging Drugs, Latest ...

Join a Clinical Trial Investigating a New Medication to Prevent Nighttime Lows

Hypoglycemia Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approva

Zucara Therapeutics Doses First Patient in Phase 2a 'ZONE' Trial

Stakeholders want FDA to consider latest advancements in ...

Zucara Therapeutics Receives IND Clearance for Phase 2 Clinical Trial of ZT-01

United States

HTML5

Google Fonts

Bootstrap

Wordpress

jQuery

Vimeo

Microsoft Outlook

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 13, 2024 11:15 AM	04b89b6c
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 13, 2024 11:15 AM	76f143d8
crunchbase trigger	general	Nov 13, 2024 11:15 AM	0730f369
crunchbase profile	general	Nov 14, 2024 10:43 AM	1e60c6ed
li profile	general	Nov 13, 2024 11:15 AM	3bcf6f22
translate crunchbase fundingrounds	general	Nov 14, 2024 11:19 AM	3966f05c
peers	general	Nov 13, 2024 11:15 AM	778c4d19
news basic	general	Nov 13, 2024 11:15 AM	c74c911b
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

ZUCA

CA:ZUCARA

Zucara Therapeutics